We are live on ! Find out more
KTTAW icon

Pasithea Therapeutics Warrants
KTTAW

2 hedge funds and large institutions have $48.7K invested in Pasithea Therapeutics Warrants in 2023 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% less capital invested

Capital invested by funds: $49.6K → $48.7K (-$855)

1.26% less ownership

Funds ownership: 6.12% → 4.86% (-1.3%)

33% less funds holding

Funds holding: 3 → 2 (-1)

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$40K – +1 +0%
WAM
2
Warberg Asset Management
Illinois
$8.7K – – –

KTTAW Hedge Fund Activity: Q1 2023 in Review

2 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics Warrants (KTTAW) for Q1 2023, worth a combined $48.7K — down 1.7% from $49.6K a quarter earlier.

Fund positioning in KTTAW was balanced in Q1 2023: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.

  • 2 institutional investors held Pasithea Therapeutics Warrants (KTTAW) as of Q1 2023, down from 3 in Q4 2022.
  • Funds reported $48.7K of Pasithea Therapeutics Warrants stock for Q1 2023, down 1.7% quarter-over-quarter.
  • 0 funds opened new Pasithea Therapeutics Warrants positions in Q1 2023 and 0 closed out.

Based on aggregated 13F filings for Q1 2023.